Most Read Articles
Jairia Dela Cruz, 2 days ago
In patients with heart failure with reduced ejection fraction (HFrEF) receiving angiotensin-converting-enzyme (ACE) inhibitors, high dosing confers benefits for the risk of death or hospitalization that are similar to that obtained with lower dosing, according to a systematic review and meta-analysis.
11 Sep 2020
Men who use calcium channel blockers (CCBs) are at risk of developing prostate cancer, and the risk increases with the duration of CCB exposure, according to the results of a systematic review and meta-analysis.
06 Sep 2020
Type 2 diabetes mellitus patients taking proton pump inhibitors (PPIs) are at a higher risk of sustaining hip fractures, a recent study has found.
4 days ago
Osteoarthritis (OA) is the most common condition affecting the joints. Dr Lee Eu Jin, an Orthopaedic Surgeon from Liberty Orthopaedic Clinic at Mount Elizabeth Medical Centre, Singapore, shares his insights with Pearl Toh on how to manage OA in the primary care setting.


Lorcaserin shows therapeutic potential in patients with impulsive aggressive behaviour

05 Feb 2020

The 5-HT2c receptor agonist lorcaserin has the potential to be repurposed for the treatment of impulsive aggression in humans, as shown in a pilot study.

Ten male and female adults with impulsive aggressive behaviour were randomly assigned to receive lorcaserin 20 mg or a matching placebo for 2 days separated by at least a 7-day washout. Researchers evaluated aggressive responding using the Taylor aggression paradigm, where patients competed against a fictitious opponent in a reaction time game during which electric shock was administered and received.

All participants had high aggression scores on the Life History of Aggression assessment (mean, 20.3) and the Buss-Perry Aggression questionnaire (mean, 47.6) relative to mean scores of 6.4 and 30.7, respectively, in nonaggressive participants reported in the literature.

Compared with placebo, lorcaserin mitigated provoked, but not unprovoked, aggression during the Taylor aggression paradigm. This was demonstrated by significant reductions in the mean frequency of selecting “high/extreme” shock levels against the opponent (7.30 with placebo vs 2.50 with the active drug; p=0.030).

The findings provide a rationale to conduct a double-blind clinical trial of lorcaserin in impulsively aggressive individuals to establish the potential antiaggressive effect of the drug, according to the researchers.

“[T]hat lorcaserin may have antiaggressive properties is consistent with the serotonin hypothesis of aggression that posits that agents that increase serotonergic activity will reduce impulsively aggressive behaviour,” they explained.  (Coccaro et al., 1989; Coccaro, Lee, & Kavoussi, 2010).

However, the researchers also pointed out that “as a receptor agonist, lorcaserin may work when selective serotonin reuptake inhibitors are not effective, especially in cases where postsynaptic serotonin (eg, 5-HT2c) receptors are highly downregulated.”

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Jairia Dela Cruz, 2 days ago
In patients with heart failure with reduced ejection fraction (HFrEF) receiving angiotensin-converting-enzyme (ACE) inhibitors, high dosing confers benefits for the risk of death or hospitalization that are similar to that obtained with lower dosing, according to a systematic review and meta-analysis.
11 Sep 2020
Men who use calcium channel blockers (CCBs) are at risk of developing prostate cancer, and the risk increases with the duration of CCB exposure, according to the results of a systematic review and meta-analysis.
06 Sep 2020
Type 2 diabetes mellitus patients taking proton pump inhibitors (PPIs) are at a higher risk of sustaining hip fractures, a recent study has found.
4 days ago
Osteoarthritis (OA) is the most common condition affecting the joints. Dr Lee Eu Jin, an Orthopaedic Surgeon from Liberty Orthopaedic Clinic at Mount Elizabeth Medical Centre, Singapore, shares his insights with Pearl Toh on how to manage OA in the primary care setting.